cervomed.com (CRVO): Growth-Adjusted Payback Ratio

Corporate company logo of CervoMed Corporation (CRVO)

The absence of commercial products deprives CervoMed Inc. (CRVO) of pricing power. The growth-weighted P/E illustrates the current valuation of the asset, where 0.00 serves as the final level mark. Business development relies on external execution of synthesis and testing. Success depends on patents and cognitive data, rendering the company sensitive to investment inflows.

CervoMed Inc. - CRVO Price/Earnings to Growth Ratio (period 02/21/2024 - 11/14/2026)

Analytical breakdowns for CervoMed Inc. (CRVO)

- current quotes and average value forecast:
General company analysis:CervoMed, Inc. (CRVO)
Original product of CervoMed Inc

For CervoMed Inc. (CRVO), this growth company undervaluation metric serves as a tool for analyzing capitalization efficiency. The indicator compares the P/E market multiple with net income growth rates. Values below one signal a potential discount of the asset relative to its expansion. In the case of CervoMed Inc. (CRVO), the calculation is extremely sensitive to the success of dementia treatment programs. High pipeline concentration makes this metric an indicator of binary risk.

Who CervoMed Inc. competes with

BIIB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Growth-Adjusted Payback Ratio RGC|AXSM: Price/Earnings to Growth Multiple|ACAD: Price/Earnings to Growth Ratio|Xenon (XENE) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Viking Therapeutics Inc (VKTX)|Price/Earnings to Growth Ratio Supernus Pharma|Price/Earnings to Growth Multiple Catalyst Corp (CPRX)|PEG Multiple DNLI|HRMY - Price to Earnings Adjusted for Growth Rate|PEG Multiple BHVN (Biohaven)|AMLX: Growth-Adjusted P/E Ratio|TRVI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|AVXL: PEG Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Prothena Corporation plc|Growth-Adjusted P/E Ratio ALEC (Alector Therapeutics)|PEG Multiple ANNX|Price/Earnings to Growth Multiple omeros.com OMER|Neurogene Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income acimmune.com (ACIU)|Voyager Therapeutics, Inc. - PEG Multiple|Neumora (NMRA) - Price/Earnings to Growth Multiple|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|Tevogen Bio Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple ACOG|Price/Earnings to Growth Ratio CGTX|Price/Earnings to Growth Ratio Inhibikase Therapeutics, Inc. (IKT)|SAVA - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Assertio ASRT|COYA: Growth-Adjusted P/E Ratio|VistaGen Therapeutics Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals, Inc.) - Price/Earnings to Growth Multiple|Alterity Therapeutics Limited (ATHE) - PEG Multiple|Price/Earnings to Growth Ratio Clene Inc|PEPG: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Jupiter Neurosciences Inc (JUNS)|RLMD - Price to Earnings Adjusted for Growth Rate|PEG Multiple ANVS (Annovis Bio)|GRCE - Price/Earnings to Growth Multiple|Firefly Neuroscience Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Price/Earnings to Growth Ratio|revivapharma.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple MTVA|Price/Earnings to Growth Ratio NRXS|Price/Earnings to Growth Ratio Helius Medical (HSDT)|PASG - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neuphoria Therapeutics NEUP|NERV - Price/Earnings to Growth Multiple|Athira Pharma - PEG Multiple|Price to Earnings Adjusted for Growth Rate Addex Therapeutics Ltd.|ALZN: PEG Multiple|Growth-Adjusted P/E Ratio CYCN|Price/Earnings to Growth Multiple PTIX|KTTA: Growth-Adjusted Payback Ratio|PEG Multiple CRGT|Growth-Adjusted Market Cap to Net Income Avenue Therapeutics Inc.|Price/Earnings to Growth Ratio Brainstorm Cell Therapeutics, Inc. BCLI|CARA: Growth-Adjusted P/E Ratio|Chromocell Therapeutics - PEG Multiple|Eliem Therapeutics (ELYM) - Price/Earnings to Growth Multiple|ITCI (intracellulartherapies.com) - Price/Earnings to Growth Multiple|LBPH - Growth-Adjusted Market Cap to Net Income|MRNS (Marinus) - PEG Multiple|Price/Earnings to Growth Multiple NKGen Biotech Corp (NKGN)|Price/Earnings to Growth Ratio NeuroBo Pharmaceuticals (NRBO)|SAGE (sagerx.com) - Growth-Adjusted Payback Ratio|Synaptogenix - Price/Earnings to Growth Multiple|Trevena Inc. - Price/Earnings to Growth Ratio|VIGL - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Anew Medical Inc.|Cerevel Therapeutics (CERE) - Price/Earnings to Growth Ratio